Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798679 · ClinicalTrials.gov registry record
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
A clinical trial of Cardiotoxicity, sponsored by University of Minnesota.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT02798679: Completed study of Cardiotoxicity, sponsored by University of Minnesota.
NCT02798679 is a study of Cardiotoxicity that has completed, run by University of Minnesota. The registered enrollment target is 40 participants, below the 645-participant average among 13 other Cardiotoxicity trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02798679, a study of Cardiotoxicity, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
Conditions Studied
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-08 |
| Est. Completion | 2022-09-01 |
What the finished NCT02798679 record still lists
NCT02798679 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 645-participant average among 13 other Cardiotoxicity trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Cardiotoxicity appearing as the primary indexed condition, and to 0 interventions.
NCT02798679 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02798679 about?
NCT02798679 is a clinical study titled "Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity". The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
What is the current status of trial NCT02798679?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2016-08. Estimated completion is 2022-09-01.
What conditions does trial NCT02798679 study?
This clinical trial studies the following conditions: Cardiotoxicity.
Who is sponsoring clinical trial NCT02798679?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02798679 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiotoxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02798679's enrollment target sits among peer trials
40 12th of 13 higher than 2 of 13 other Cardiotoxicity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiotoxicity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Global Cardio Oncology Registry
RECRUITING
-
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
RECRUITING
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
A Study of Blood Pressure Control During Cancer Treatment
RECRUITING · Phase 2
-
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia